Amneal Pharmaceuticals, Inc. (AMRX)

USD 7.69

(-4.71%)

Operating Expenses Summary of Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.'s latest annual operating expenses in 2023 was 616.19 Million USD , up 0.09% from previous year.
Amneal Pharmaceuticals, Inc.'s latest quarterly operating expenses in 2024 Q1 was 151.89 Million USD , down -2.36% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a annual operating expenses of 595.78 Million USD in annual operating expenses 2022, up 3.6% from previous year.
Amneal Pharmaceuticals, Inc. reported a annual operating expenses of 575.06 Million USD in annual operating expenses 2021, up 11.16% from previous year.
Amneal Pharmaceuticals, Inc. reported a quarterly operating expenses of 167 Million USD for 2024 Q2, up 9.95% from previous quarter.
Amneal Pharmaceuticals, Inc. reported a quarterly operating expenses of 596.31 Million USD for 2023 FY, up 0.09% from previous quarter.

Annual Operating Expenses Chart of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Historical Annual Operating Expenses of Amneal Pharmaceuticals, Inc. (2023 - 2014)

Year	Operating Expenses	Operating Expenses Growth
2023	616.19 Million USD	0.09%
2022	595.78 Million USD	3.6%
2021	575.06 Million USD	11.16%
2020	517.31 Million USD	5.17%
2019	491.88 Million USD	11.57%
2018	440.88 Million USD	46.48%
2017	300.98 Million USD	-6.96%
2016	323.5 Million USD	16.45%
2015	277.8 Million USD	15.93%
2014	239.63 Million USD	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	151.89 Million USD	-2.36%
2024 Q2	167 Million USD	9.95%
2023 FY	596.31 Million USD	0.09%
2023 Q4	155.56 Million USD	0.15%
2023 Q1	141.2 Million USD	-1.91%
2023 Q3	155.34 Million USD	7.72%
2023 Q2	144.2 Million USD	2.12%
2022 Q1	152.22 Million USD	1.32%
2022 FY	595.78 Million USD	3.6%
2022 Q4	143.96 Million USD	-4.28%
2022 Q3	150.39 Million USD	0.8%
2022 Q2	149.2 Million USD	-1.99%
2021 Q3	141.95 Million USD	1.11%
2021 Q4	150.24 Million USD	5.84%
2021 Q2	140.38 Million USD	-1.48%
2021 Q1	142.49 Million USD	0.45%
2021 FY	575.06 Million USD	11.16%
2020 Q2	130.06 Million USD	12.49%
2020 Q4	141.84 Million USD	9.3%
2020 FY	517.31 Million USD	5.17%
2020 Q3	129.77 Million USD	-0.23%
2020 Q1	115.62 Million USD	-9.03%
2019 Q2	117.8 Million USD	-17.3%
2019 Q4	127.1 Million USD	21.63%
2019 FY	491.88 Million USD	11.57%
2019 Q1	142.46 Million USD	8.11%
2019 Q3	104.5 Million USD	-11.29%
2018 Q2	107.38 Million USD	45.3%
2018 FY	440.88 Million USD	46.48%
2018 Q4	131.77 Million USD	5.02%
2018 Q3	125.47 Million USD	16.85%
2018 Q1	73.9 Million USD	0.98%
2017 FY	300.98 Million USD	-6.96%
2017 Q1	52.42 Million USD	-47.99%
2017 Q2	79.04 Million USD	50.79%
2017 Q3	75.45 Million USD	-4.54%
2017 Q4	73.19 Million USD	-3.0%
2016 Q4	100.79 Million USD	0.0%
2016 FY	323.5 Million USD	16.45%
2015 FY	277.8 Million USD	15.93%
2014 FY	239.63 Million USD	0.0%

Peer Operating Expenses Comparison of Amneal Pharmaceuticals, Inc.

Name	Operating Expenses	Operating Expenses Difference
Bausch Health Companies Inc.	5.23 Billion USD	88.229%
Catalent, Inc.	1.7 Billion USD	63.796%
Emergent BioSolutions Inc.	1.04 Billion USD	40.978%
Elanco Animal Health Incorporated	1.61 Billion USD	61.775%
Perrigo Company plc	1.52 Billion USD	59.687%
Teva Pharmaceutical Industries Limited	4.45 Billion USD	86.156%
Zoetis Inc.	2.76 Billion USD	77.715%